Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved for HIV-associated lipodystrophy. One of the few peptides with a clear FDA-approved indication, making it a useful reference point for the broader GHRH analog class.
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone. Available with or without a Drug Affinity Complex (DAC) that extends its half-life.
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile GH release. Reduces visceral adipose tissue (VAT) through GH-mediated lipolysis. Maintains the natural pulsatile pattern of GH secretion, preserving feedback mechanisms.
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile release of growth hormone. The DAC version binds to albumin in the blood, extending the half-life from minutes to approximately 6-8 days.
- HIV-associated lipodystrophy (FDA-approved)
- Visceral fat reduction
- Metabolic health improvement
- Growth hormone optimization (off-label)
- Cognitive function (emerging research in older adults)
- Growth hormone optimization
- Improved sleep quality
- Fat loss
- Muscle recovery
- Anti-aging protocols
- Injection site reactions (common)
- Fluid retention and edema
- Arthralgia (joint pain)
- Potential glucose metabolism effects
- Contraindicated in active malignancy
- Water retention
- Tingling or numbness
- Potential cortisol elevation
- Limited long-term safety data
- May affect blood sugar levels
FDA-approved as Egrifta (tesamorelin for injection) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also available through compounding pharmacies for off-label use with a physician prescription.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.